Overview

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Status:
Not yet recruiting

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.

Phase:

N/A

Details

Lead Sponsor:

First Affiliated Hospital of Zhejiang University

Collaborator:

Ascletis Pharmaceuticals Co., Ltd.

Treatments:

Lopinavir
Ritonavir